Samsung Bioepis Co., a biosimilar medicine developer under Samsung Group, has released its biosimilar product for autoimmune disease treatment Stelara in Europe, the company's marketing partner said Friday. Pyzchiva, a treatment for plaque psoriasis, Crohn's disease, active psoriatic arthritis and ulcerative colitis, is Samsung Bioepis' eighth biosimilar product that has hit the European market, according to Sandoz Group. Samsung Bioepis currently sells four autoimmune disease treatments, including Pyzchiva, two anti-cancer treatments, one eye disease treatment and one blood disease treatment in Europe. Source: Yonhap News Agency
CPC Maintains Fuel Prices Despite Global Oil Market Fluctuations
October 17, 2026